National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 2 of 2 Research Studies DisplayedMisch EA, Safdar N
Clostridioides difficile infection in the stem cell transplant and hematologic malignancy population.
This article describes a study underway with patients who have undergone a stem cell transplant due to a hematologic malignancy who subsequently contracted a Clostridioides difficile (CD) infection. A new treatment for CD infection is the use of a fecal microbiota transplant (FMT), but it has not been widely adopted in transplant patients because of safety concerns. A randomized controlled trial of FMT in transplant patients is now underway.
AHRQ-funded; HS026226; HS025713.
Citation: Misch EA, Safdar N .
Clostridioides difficile infection in the stem cell transplant and hematologic malignancy population.
Infect Dis Clin North Am 2019 Jun;33(2):447-66. doi: 10.1016/j.idc.2019.02.010..
Keywords: Clostridium difficile Infections, Healthcare-Associated Infections (HAIs), Cancer
Cannon CM, Musuuza JS, Barker AK
Risk of Clostridium difficile infection in hematology-oncology patients colonized with toxigenic C. difficile.
This study determined that the prevalence of colonization with toxigenic Clostridium difficile among patients with hematological malignancies and/or bone marrow transplant at admission to a 566-bed academic medical care center was 9.3 percent. Thirteen percent of colonized patients developed symptomatic disease during hospitalization. This population may benefit from targeted C. difficile infection control interventions.
AHRQ-funded; HS024039; HS023791.
Citation: Cannon CM, Musuuza JS, Barker AK .
Risk of Clostridium difficile infection in hematology-oncology patients colonized with toxigenic C. difficile.
Infect Control Hosp Epidemiol 2017 Jun;38(6):718-20. doi: 10.1017/ice.2017.48.
.
.
Keywords: Cancer, Clostridium difficile Infections, Healthcare-Associated Infections (HAIs), Patient Safety, Risk